Clinical Trials Browser

Not yet recruiting × Interventional × Mesothelioma, Malignant × Clear all

Immunoglobulin Light-chain Amyloidosis, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Carcinoma, Bronchogenic, Heart Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Follicular, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT07234058 2026-02-11

LAG-MAPS

Phase 2 Not yet recruiting

126 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT07282873 2025-12-22

Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

219 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT07131345 2025-08-20

Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma

Phase 1/2 Not yet recruiting

55 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT06416930 2024-05-16

Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma

Phase 2 Not yet recruiting

59 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05425576 2024-03-15

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Phase 2 Not yet recruiting

63 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05698238 2023-03-15

CAMP1

Phase 1 Not yet recruiting

50 enrolled

BreastGenitourinaryHead & NeckOther solid neoplasmThoracic

Clear-cell metastatic renal cell carcinoma, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

ETCABIO

LAG-MAPS

Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors

Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma

Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

CAMP1